%0 Journal Article
%T Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
%A Landgren O
%A Weisel K
%A Rosinol L
%A Touzeau C
%A Turgut M
%A Hajek R
%A Mollee P
%A Kim JS
%A Shu N
%A Hu X
%A Li C
%A Usmani SZ
%J Br J Haematol
%V 198
%N 6
%D 09 2022
%M 35608261
%F 8.615
%R 10.1111/bjh.18233
%X CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.